Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.61 |
| ▸ | PDE4A | P27815 | 17/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442028 | 1.00 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL2798678 | 1.00 | PDE4D (0.61) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL2799424 | 0.90 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4436530 | 0.90 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2800836 | 0.90 | PDE4D (0.58) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2799239 | 0.90 | PDE4A (0.57) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2799305 | 0.90 | PDE4A (0.57) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL4448611 | 0.90 | PDE4A (0.57) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL2799568 | 0.89 | PDE4A (0.57) | PDE4DPDE4APDE4BPDE4CKDM4E | |
| SCHEMBL2800190 | 0.87 | PDE4A (0.54) | PDE4DPDE4APDE4BPDE4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2137150-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110794-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168170-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | PDE4D 1120/4885PDE4A 696/4885PDE4B 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.